Hypoxic Ischaemic Encephalopathy (HIE)

1. Clinical Overview

Summary

Hypoxic Ischaemic Encephalopathy (HIE) is a clinically defined syndrome of disturbed neurological function in term and late preterm neonates, manifesting as difficulty initiating and maintaining respiration, depression of tone and reflexes, and abnormal level of consciousness. [1] It results from an acute perinatal hypoxic-ischaemic event causing insufficient oxygen delivery to the brain and other organs, leading to a characteristic biphasic pattern of cerebral injury. [2,3]

HIE represents the leading cause of acquired neonatal brain injury worldwide, accounting for 23% of the estimated 2.5 million global neonatal deaths annually and affecting 1-3 per 1000 live births in high-income countries. [4,5] Despite advances in obstetric and neonatal care, HIE remains a devastating condition associated with significant mortality (10-60% depending on severity) and long-term neurodevelopmental impairment in 25-50% of survivors. [6]

The pathophysiology involves two distinct phases: an immediate primary energy failure during the hypoxic-ischaemic insult, followed by a delayed secondary energy failure occurring 6-48 hours after resuscitation. This biphasic injury pattern creates a crucial therapeutic window during which neuroprotective interventions can modify outcome. [7,8] Therapeutic hypothermia, initiated within 6 hours of birth and maintained for 72 hours, represents the only established treatment with proven efficacy in reducing death and disability. [9,10]

Key Facts

Defining Criteria for HIE

• Sentinel hypoxic event: Uterine rupture, placental abruption, cord prolapse, shoulder dystocia, maternal collapse
• Fetal compromise: Pathological cardiotocography (CTG), fetal bradycardia, thick meconium
• Metabolic acidosis: Umbilical artery pH less than 7.0 or base deficit ≥ 12 mmol/L
• Apgar scores: ≤ 5 at 10 minutes or ongoing resuscitation at 10 minutes
• Neurological dysfunction: Altered consciousness, abnormal tone, seizures, feeding difficulties
• Multi-organ involvement: Kidney, liver, heart, gut, bone marrow, lungs [11]

Sarnat Staging System The modified Sarnat classification divides HIE into three grades based on neurological examination:

• Stage 1 (Mild): Hyperalert, mild hypotonia, brisk reflexes, sympathetic overdrive (tachycardia, mydriasis), no seizures. Duration less than 24 hours. Excellent prognosis. Does not qualify for therapeutic hypothermia. [12]

• Stage 2 (Moderate): Lethargy or obtundation, marked hypotonia, weak primitive reflexes, miosis, seizures (often present), require tube feeding. Qualifies for cooling. Risk of adverse outcome 30-50% without treatment. [12]

• Stage 3 (Severe): Stupor or coma, flaccid tone, absent primitive reflexes, fixed dilated pupils, requires ventilation, clinical or electrical seizures. Qualifies for cooling. Risk of death or severe disability 75-90%. [12]

The Therapeutic Window The latent phase between primary and secondary energy failure provides a 6-hour window from birth during which therapeutic hypothermia must be initiated. After 6 hours, the cascade of secondary injury mechanisms (excitotoxicity, oxidative stress, inflammation, apoptosis) becomes irreversible. [13] Passive cooling (turning off radiant warmer) should begin immediately while arranging transfer to a cooling centre.

Clinical Pearls

Time-Critical Neuroprotection: Every hour of delay in initiating therapeutic hypothermia within the first 6 hours reduces efficacy. Passive cooling during stabilization and transfer is essential. Target rectal temperature 33-34°C for passive cooling, 33.5°C for active cooling.

aEEG is Prognostic and Therapeutic: Amplitude-integrated EEG provides continuous bedside monitoring. Burst suppression, continuous low voltage, or flat trace patterns predict poor outcome and guide cooling decisions. Normal voltage trace within 24 hours predicts favourable outcome. [14]

MRI Timing Matters: Early MRI (less than 4 days) may underestimate injury. Optimal timing is 4-10 days when injury patterns are established. Basal ganglia-thalamus predominant injury indicates profound acute insult; watershed predominant injury suggests partial prolonged hypoxia-ischaemia. [15]

Multi-organ Involvement is the Rule: HIE is a systemic condition. Check renal function (acute tubular necrosis in 50%), liver enzymes (hepatic injury 40%), cardiac enzymes (myocardial dysfunction 30%), platelets (DIC 20%), and blood glucose (persistent hypoglycaemia indicates severe injury). [16]

Don't Forget the Obstetric History: Accurate documentation of intrapartum events is crucial for diagnosis, prognosis, and potential medicolegal review. Timing of sentinel event, CTG abnormalities, cord gases, Apgar scores, and resuscitation details must be meticulously recorded.

---

2. Epidemiology

Incidence and Prevalence

Global Burden

• Worldwide incidence: 1.5 per 1000 live births (pooled estimate from systematic reviews) [5]
• High-income countries: 1-3 per 1000 live births [4]
• Low- and middle-income countries: 5-10 per 1000 live births [17]
• Accounts for approximately 23% of global neonatal deaths (800,000-900,000 deaths annually) [4]
• Leading cause of neonatal mortality after preterm birth complications and infections

Mortality and Morbidity

• Overall mortality: 10-60% (varies with severity and access to cooling)
• Moderate HIE mortality: 10% with cooling, 20% without
• Severe HIE mortality: 50-60% despite cooling
• Neurodevelopmental impairment in survivors: 25-50% (cerebral palsy, intellectual disability, epilepsy) [6]

Risk Factors

Antepartum Risk Factors

• Maternal factors: Pre-eclampsia, diabetes, thyroid disease, substance abuse, thrombophilia
• Placental factors: Placental insufficiency, abruption, vasa praevia
• Fetal factors: Intrauterine growth restriction, multiple pregnancy, reduced fetal movements, oligohydramnios
• Previous stillbirth or neonatal death [18]

Intrapartum Risk Factors (Sentinel Events)

• Placental abruption: 40% of cases, associated with severe HIE
• Uterine rupture: Rare but catastrophic, 50% risk of HIE
• Cord prolapse: 15-20% risk of HIE if delivery delayed
• Shoulder dystocia: 2-5% risk with prolonged head-to-body delivery
• Maternal hypotension/collapse: Haemorrhage, amniotic fluid embolism, eclampsia
• Difficult instrumental delivery: Prolonged second stage, failed rotational forceps
• Tight nuchal cord: Multiple loops with cord occlusion [11]

Protective Factors

• Continuous intrapartum fetal monitoring (allows early detection of compromise)
• Fetal blood sampling during labour (confirmation of acidosis triggers intervention)
• Availability of emergency caesarean section (less than 30 minutes decision-to-delivery)
• Skilled neonatal resuscitation team present at high-risk deliveries [19]

---

3. Pathophysiology

Overview: The Biphasic Injury Pattern

HIE follows a characteristic two-phase injury pattern identified through magnetic resonance spectroscopy (MRS) studies and animal models. [7,8] Understanding this temporal evolution is fundamental to rational neuroprotective therapy.

Phase 1: Primary Energy Failure (During Hypoxia-Ischaemia)

Cellular Hypoxia and Anaerobic Metabolism During the acute hypoxic-ischaemic insult, cerebral oxygen delivery falls below the threshold required for oxidative phosphorylation (normal cerebral oxygen delivery in term neonate: 20-25 mL O₂/100g/min). Cells switch to anaerobic glycolysis, producing only 2 ATP molecules per glucose molecule (compared to 38 via aerobic metabolism). [20]

Consequences of Primary Energy Failure:

1. Lactate accumulation: pH falls, metabolic acidosis develops (cord pH less than 7.0)
2. Na⁺/K⁺-ATPase pump failure: Loss of ionic homeostasis, cell membrane depolarization
3. Glutamate release: Voltage-gated calcium channels open, excessive intracellular Ca²⁺ influx
4. Cytotoxic oedema: Cell swelling, reduced diffusion on MRI (restricted diffusion-weighted imaging)
5. Neurotransmitter accumulation: Excessive synaptic glutamate (excitotoxicity) [21]

If severe or prolonged (> 25 minutes of complete asphyxia), primary energy failure alone can cause neuronal necrosis. However, if circulation is restored (resuscitation), a recovery phase occurs.

Phase 2: Latent Phase (1-6 Hours)

Following successful resuscitation, cerebral oxidative metabolism partially recovers. MRS shows normalization of phosphocreatine/inorganic phosphate ratio. The infant may appear deceptively stable during this period, though subtle signs of encephalopathy (abnormal tone, poor feeding) are usually present. [8]

This latent phase represents the therapeutic window for neuroprotective interventions. Cooling initiated during this period interrupts progression to secondary energy failure.

Phase 3: Secondary Energy Failure (6-48 Hours)

Despite apparent recovery, a delayed deterioration occurs 6-48 hours after the initial insult. MRS shows progressive decline in phosphocreatine/inorganic phosphate ratio and ATP levels, accumulation of lactate, and rising intracellular pH. [7,22] This secondary phase is mediated by multiple interconnected mechanisms:

Excitotoxicity

Excessive glutamate release activates NMDA (N-methyl-D-aspartate) receptors, causing sustained Ca²⁺ influx. Intracellular Ca²⁺ overload triggers:

• Activation of proteases (calpains, caspases)
• Lipid peroxidation (membrane damage)
• Mitochondrial dysfunction
• DNA fragmentation [21]

Oxidative Stress and Free Radical Damage

Reperfusion after hypoxia-ischaemia generates reactive oxygen species (ROS) and reactive nitrogen species (RNS):

• Superoxide (O₂⁻), hydrogen peroxide (H₂O₂), hydroxyl radical (•OH)
• Nitric oxide (NO) reacts with superoxide to form peroxynitrite (ONOO⁻)
• Neonatal brain particularly vulnerable due to:
  • High iron content (Fenton reaction generating hydroxyl radicals)
  • Low antioxidant enzyme activity (superoxide dismutase, catalase, glutathione peroxidase)
  • High polyunsaturated fatty acid content in membranes (lipid peroxidation targets) [23]

Inflammation

Activated microglia and astrocytes release pro-inflammatory cytokines:

• Tumour necrosis factor-α (TNF-α)
• Interleukin-1β (IL-1β), IL-6, IL-8
• Chemokines attracting peripheral leukocytes
• Complement activation and blood-brain barrier disruption
• Inflammatory response peaks at 24-48 hours, contributing to secondary neuronal loss [24]

Apoptosis (Programmed Cell Death)

In addition to necrotic cell death during primary energy failure, delayed apoptosis occurs over days to weeks:

• Intrinsic (mitochondrial) pathway: Cytochrome c release, caspase-9 and caspase-3 activation
• Extrinsic (death receptor) pathway: Fas/FasL and TNF receptor activation
• Apoptosis particularly affects oligodendrocytes (white matter injury) and neurons in watershed zones
• Represents a target for therapeutic intervention (caspase inhibitors in experimental studies) [25]

Impaired Cerebrovascular Autoregulation

Normal cerebrovascular autoregulation maintains constant cerebral blood flow across a range of systemic blood pressures (mean arterial pressure 30-60 mmHg in term neonates). After HIE, autoregulation is impaired for 24-72 hours, making cerebral perfusion pressure-passive:

• Hypotension → cerebral hypoperfusion → extension of injury
• Hypertension → hyperaemia, cerebral oedema, haemorrhage
• Careful blood pressure management essential during cooling [26]

Regions of Selective Vulnerability

Different brain regions exhibit varying susceptibility to hypoxic-ischaemic injury based on metabolic demand, vascular supply, and developmental stage:

Profound Acute Hypoxia-Ischaemia (e.g., cord prolapse, complete abruption):

• Basal ganglia (putamen, caudate) and thalami (ventrolateral nuclei)
• Highest metabolic rate and dense glutamate receptors
• Results in dyskinetic cerebral palsy [15]

Partial Prolonged Hypoxia-Ischaemia (e.g., placental insufficiency, sentinel event during labour):

• Watershed (parasagittal) cortex and subcortical white matter
• Border zones between anterior/middle and middle/posterior cerebral artery territories
• Results in spastic quadriplegia [15]

Perirolandic Cortex:

• Motor and sensory cortex particularly vulnerable
• Explains motor deficits even with mild-moderate injury

Brainstem:

• Severe cases: involvement of cranial nerve nuclei, respiratory centres
• Correlates with poor outcome and death [27]

Mechanisms of Therapeutic Hypothermia

Cooling to 33-34°C reduces cerebral metabolic rate by approximately 5-8% per 1°C decrease. Multiple neuroprotective mechanisms contribute to improved outcomes: [28]

1. Reduced metabolic demand: Lower ATP requirement, preservation of high-energy phosphates
2. Decreased excitotoxicity: Reduced glutamate release and NMDA receptor activity
3. Antioxidant effects: Decreased free radical production, enhanced endogenous antioxidant systems
4. Anti-inflammatory: Reduced cytokine release, decreased microglial activation
5. Anti-apoptotic: Reduced caspase activation, preserved mitochondrial integrity
6. Preserved autoregulation: Partial restoration of cerebrovascular autoregulation
7. Reduced seizure burden: Anticonvulsant effect of hypothermia [9,10]

---

4. Clinical Presentation

Immediate Postnatal Period (Delivery Room)

Resuscitation Requirements The hallmark of significant perinatal hypoxia-ischaemia is failure to establish adequate spontaneous respirations despite appropriate resuscitation:

• Persistent apnoea or gasping respirations at birth
• Requirement for positive pressure ventilation > 10 minutes
• Requirement for chest compressions
• Requirement for emergency intubation
• Poor response to resuscitation efforts (ongoing bradycardia, hypotension) [11]

Apgar Scores Apgar scores at 1, 5, and 10 minutes provide standardized assessment of transition:

• 1 minute: Reflects intrapartum events and immediate adaptation
• 5 minutes: Apgar ≤ 5 suggests ongoing compromise
• 10 minutes: Apgar ≤ 5 highly predictive of HIE and adverse neurodevelopmental outcome
• Each additional minute with Apgar 0-3 after 10 minutes increases mortality risk [29]

Cord Blood Gases Umbilical artery sampling immediately after delivery provides objective evidence of metabolic status during labour:

• pH less than 7.0: Severe acidosis, strong association with HIE
• Base deficit ≥ 12 mmol/L: Indicates significant metabolic acidosis
• Lactate ≥ 11 mmol/L: Alternative marker of anaerobic metabolism
• pH 7.0-7.1 with base deficit 10-12: Moderate acidosis, consider cooling if clinical encephalopathy present [11]

First 6 Hours: The Critical Assessment Period

Detailed neurological examination is performed to determine presence and severity of encephalopathy. Examination should be repeated every 2-4 hours during the decision-making period for cooling.

Modified Sarnat Examination

Level of Consciousness

• Stage 1: Hyperalert, exaggerated startle response, easily roused
• Stage 2: Lethargic, decreased spontaneous activity, requires stimulation to rouse
• Stage 3: Stuporous or comatose, no response to stimulation, unconscious

Neuromuscular Control

Posture and Tone

• Stage 1: Mild distal flexion, slight hypotonia
• Stage 2: Marked hypotonia, frog-leg posture, head lag on pull-to-sit
• Stage 3: Flaccid, no resistance to passive movement, opisthotonos (if seizures)

Primitive Reflexes

• Moro reflex:

  • "Stage 1: Exaggerated, low threshold"
  • "Stage 2: Weak, incomplete, high threshold"
  • "Stage 3: Absent"

• Suck reflex:

  • "Stage 1: Weak"
  • "Stage 2: Weak or absent, unable to feed"
  • "Stage 3: Absent"

• Grasp reflex:

  • "Stage 1: Normal"
  • "Stage 2: Decreased"
  • "Stage 3: Absent"

Autonomic Function

• Pupils:

  • "Stage 1: Mydriasis (dilated), reactive"
  • "Stage 2: Miosis (constricted), sluggishly reactive"
  • "Stage 3: Fixed, dilated, or pinpoint unreactive"

• Heart rate:

  • "Stage 1: Tachycardia (sympathetic overdrive)"
  • "Stage 2: Bradycardia (parasympathetic predominance)"
  • "Stage 3: Variable, requires inotropic support"

• Respirations:

  • "Stage 1: Spontaneous, may have tachypnoea"
  • "Stage 2: Periodic breathing, apnoeas"
  • "Stage 3: Apnoea, requires mechanical ventilation"

Seizures

• Stage 1: None
• Stage 2: Common (50-70% of moderate HIE), focal clonic or subtle seizures
• Stage 3: Frequent, often only electrical seizures detected on EEG (clinical seizures may be absent due to profound encephalopathy) [12]

Evolution Beyond 6 Hours

6-24 Hours

• Stage 2-3 encephalopathy persists or worsens
• Seizures typically onset 12-24 hours (may be earlier in severe cases)
• Multi-organ dysfunction becomes apparent
• Coagulopathy, thrombocytopenia, hepatic dysfunction
• Acute kidney injury (oliguria, rising creatinine)

24-72 Hours (During Cooling)

• Peak of secondary energy failure
• Maximal seizure burden
• aEEG background may show transient improvement or further deterioration
• Continued multi-organ supportive care required

72 Hours - Rewarming

• Gradual rewarming at 0.5°C per hour over 6-8 hours
• Risk of rebound hypotension, seizures, hyperkalaemia during rewarming
• Close cardiovascular and neurological monitoring

Beyond 72 Hours

• Stage 1: Complete resolution, normal examination, discharge planning
• Stage 2: Gradual improvement over days to weeks; ongoing hypotonia, feeding difficulties common; discharge to home or rehabilitation
• Stage 3: Persistent severe encephalopathy → decision regarding redirection of care vs ongoing intensive support; those surviving often have severe disabilities [30]

Multi-Organ Involvement

HIE is a systemic condition affecting multiple organ systems due to redistribution of cardiac output during hypoxia-ischaemia. [16]

Cardiovascular System (60-70%)

• Myocardial dysfunction (elevated troponin, BNP)
• Tricuspid regurgitation (papillary muscle ischaemia)
• Hypotension requiring inotropic support (dopamine, dobutamine, adrenaline)
• Persistent pulmonary hypertension of the newborn (PPHN) - 20-30% of moderate-severe HIE

Renal System (40-50%)

• Acute tubular necrosis (ATN)
• Oliguria (urine output less than 1 mL/kg/hour)
• Rising creatinine (> 100 μmol/L)
• Hyperkalaemia, acidosis
• May require peritoneal dialysis or haemofiltration (rare)

Hepatic System (40%)

• Elevated transaminases (AST, ALT)
• Prolonged prothrombin time (PT)
• Hypoglycaemia (impaired gluconeogenesis)
• Conjugated hyperbilirubinaemia (prolonged jaundice)

Haematological System (20-30%)

• Disseminated intravascular coagulation (DIC)
• Thrombocytopenia (less than 100 × 10⁹/L)
• Prolonged PT, APTT, low fibrinogen
• Increased risk of haemorrhage (pulmonary, gastrointestinal, intracranial)

Gastrointestinal System (10-20%)

• Feeding intolerance
• Ileus
• Necrotising enterocolitis (NEC) - especially if hypothermia delayed or prolonged hypotension

Respiratory System (30-50%)

• Persistent pulmonary hypertension (PPHN)
• Meconium aspiration syndrome (often co-exists)
• Pulmonary haemorrhage
• Surfactant deficiency (secondary to asphyxia)

Metabolic Disturbances

• Hypoglycaemia (less than 2.6 mmol/L) - common in first 24 hours, persistent hypoglycaemia indicates severe injury
• Hypocalcaemia
• Hyponatraemia (SIADH - syndrome of inappropriate ADH secretion)

---

5. Investigations

Bedside Investigations

Amplitude-Integrated EEG (aEEG)

aEEG provides continuous bedside monitoring of cerebral electrical activity using 1-2 channel EEG with compressed time scale and amplitude integration. It is an essential tool for assessing encephalopathy severity, detecting seizures, and predicting outcome. [14,31]

Normal aEEG Patterns

• Continuous normal voltage (CNV): Upper margin 10-50 μV, lower margin 5-10 μV
• Indicates normal background activity, excellent prognosis

Abnormal aEEG Patterns

• Discontinuous normal voltage (DNV): Periods of normal voltage alternating with lower voltage; acceptable in first 24-48 hours if improving
• Burst suppression (BS): Bursts of high-amplitude activity alternating with very low voltage or isoelectric periods; indicates severe encephalopathy
• Continuous low voltage (CLV): Upper margin less than 10 μV, lower margin less than 5 μV; indicates severe injury
• Flat trace (FT): Both margins less than 5 μV; indicates profound injury, very poor prognosis

Prognostic Value

• Normal voltage pattern within 24 hours: > 90% normal outcome
• Persistent burst suppression or worse at 48 hours: > 80% death or severe disability
• Recovery to continuous normal voltage by 24-36 hours: favourable outcome likely [14]

Seizure Detection

• aEEG detects increased seizure burden (saw-tooth pattern)
• Sensitivity 70-80% for seizures > 30 seconds
• Conventional multi-channel EEG superior for brief or focal seizures

Conventional Electroencephalography (EEG)

Multi-channel EEG provides detailed assessment of background activity, sleep-wake cycling, and seizure detection:

• Performed if aEEG unavailable or for detailed seizure characterization
• Background patterns: normal, mildly abnormal (excessive discontinuity), moderately abnormal (burst suppression), severely abnormal (isoelectric, low voltage)
• Seizure types: focal clonic, multifocal clonic, tonic, subtle (oral automatisms, cycling movements)
• Prognostic significance similar to aEEG [32]

Point-of-Care Tests

Blood Glucose

• Monitor hourly in first 6 hours, then 4-hourly
• Target 2.6-10 mmol/L
• Persistent hypoglycaemia (less than 2.6 mmol/L despite adequate glucose infusion) indicates severe brain injury and hepatic dysfunction

Blood Gas Analysis

• Umbilical artery gas immediately after delivery (diagnosis)
• Arterial or capillary gases every 4-6 hours (monitor acidosis, lactate, electrolytes)
• Target pH 7.35-7.45, lactate less than 2 mmol/L during cooling

Lactate

• Elevated lactate (> 5 mmol/L) at 12-24 hours associated with worse outcome
• Serial lactate measurements help assess adequacy of resuscitation and organ perfusion

Laboratory Investigations

Haematology

• Full blood count: Thrombocytopenia indicates severe HIE, DIC
• Coagulation screen (PT, APTT, fibrinogen): Assess for coagulopathy
• Blood group and cross-match (if transfusion anticipated)

Biochemistry

• Urea, creatinine, electrolytes: Daily monitoring for acute kidney injury
• Liver function tests (ALT, AST, bilirubin, albumin): Assess hepatic injury
• Calcium, magnesium, phosphate: Metabolic derangements common
• C-reactive protein (CRP): Exclude sepsis (sepsis can mimic HIE)

Cardiac

• Troponin-I or T: Elevated in myocardial dysfunction (40-60% of moderate-severe HIE)
• Brain natriuretic peptide (BNP): Correlates with severity of myocardial injury

Novel Biomarkers (Research/Emerging)

• Neuron-specific enolase (NSE): Elevated in brain injury, but lacks specificity
• S100B protein: Marker of astrocyte damage
• Glial fibrillary acidic protein (GFAP): Correlates with white matter injury
• Activin A, BDNF, tau protein: Under investigation for prognostic value [33]

Imaging Investigations

Cranial Ultrasound

Performed via anterior fontanelle, portable bedside technique:

Day 1-2

• Mainly to exclude intracranial haemorrhage, large infarcts
• HIE changes often not visible in acute phase
• May see slit-like ventricles (cerebral oedema), increased echogenicity in basal ganglia (severe cases)

Day 4-7

• Increased echogenicity in thalami, basal ganglia (predicts poor outcome)
• Cystic changes indicate established injury
• Sensitivity and specificity inferior to MRI; used for screening and monitoring [34]

Magnetic Resonance Imaging (MRI)

MRI is the gold standard imaging modality for HIE, providing detailed anatomical and functional information. Optimal timing is Day 4-10 when injury patterns are fully established. [15,35]

MRI Sequences

Conventional Sequences

• T1-weighted: Hyperintense signal in areas of injury (basal ganglia, thalamus, cortex)
• T2-weighted: Hypointense signal in basal ganglia (acute), hyperintense in white matter injury
• FLAIR (fluid-attenuated inversion recovery): Detects cortical and white matter injury

Diffusion-Weighted Imaging (DWI) and Apparent Diffusion Coefficient (ADC)

• Most sensitive for acute injury (first 7 days)
• Restricted diffusion (bright on DWI, dark on ADC) indicates cytotoxic oedema
• Patterns of restriction correlate with outcome

Magnetic Resonance Spectroscopy (MRS)

• Measures brain metabolites: N-acetyl aspartate (NAA), lactate, choline, creatine
• Reduced NAA/choline ratio indicates neuronal loss
• Elevated lactate indicates ongoing anaerobic metabolism
• Peak lactate at 1-2 weeks predicts adverse outcome [36]

Injury Patterns and Prognosis

Basal Ganglia-Thalamus (BGT) Predominant Pattern

• Signal abnormality in putamen, ventrolateral thalamus, perirolandic cortex
• Indicates profound acute hypoxia-ischaemia
• Associated with dyskinetic cerebral palsy
• Scoring systems (Barkovich, NICHD): extent of BGT injury predicts severity of motor impairment [37]

Watershed Predominant Pattern

• Injury in parasagittal cortex, subcortical white matter
• Indicates partial prolonged hypoxia-ischaemia
• Associated with spastic quadriplegia
• Better prognosis than BGT pattern if lesions limited

Focal/Multifocal Pattern

• Arterial stroke (middle cerebral artery territory)
• May co-exist with HIE or represent separate pathology (differential diagnosis)

Normal MRI

• Strong predictor of normal neurodevelopmental outcome (NPV > 95%)
• If MRI normal at day 7-10 and neurological exam normalizing, excellent prognosis [15]

MRI Scoring Systems

• Barkovich score: 0-4 scale for basal ganglia and watershed injury
• NICHD score: Detailed anatomical scoring (0-77 points)
• Validated correlation with 18-24 month neurodevelopmental outcomes [37]

Computed Tomography (CT)

Limited Role in HIE

• Not routinely indicated (inferior to MRI, radiation exposure)
• May be used emergently if MRI unavailable and intracranial haemorrhage suspected
• Findings: cerebral oedema (loss of grey-white differentiation), hypodensity in basal ganglia

Cardiac Investigations

Echocardiography

• Assess ventricular function (ejection fraction, fractional shortening)
• Tricuspid regurgitation (estimate pulmonary artery pressure, assess for PPHN)
• Exclude structural heart disease
• Guide inotrope therapy

Electrocardiography (ECG)

• Usually normal
• May show ST-segment changes, T-wave inversion if severe myocardial ischaemia

---

6. Differential Diagnosis

Not all neonatal encephalopathy is due to hypoxic-ischaemic injury. Alternative or contributing diagnoses must be considered, especially when:

• No clear sentinel event or evidence of intrapartum compromise
• Cord gases normal (pH > 7.1)
• Unusual clinical features (e.g., dysmorphism, hepatosplenomegaly, unusual metabolic derangement) [38]

Neonatal Stroke

Arterial Ischaemic Stroke

• Focal seizures (often hand/face), unilateral examination findings
• MRI: Arterial territory infarction (middle cerebral artery most common)
• May co-exist with HIE

Cerebral Sinovenous Thrombosis

• Seizures, lethargy, apnoeas
• MRI venography: Thrombosis of sagittal sinus, transverse sinus
• Risk factors: Dehydration, polycythaemia, sepsis, maternal thrombophilia

Intracranial Haemorrhage

Subdural Haemorrhage

• Traumatic delivery, instrumental delivery
• Cranial ultrasound/CT: Extra-axial blood

Intraventricular Haemorrhage (IVH)

• More common in preterm, rare in term
• Ultrasound: Blood in ventricles, grading I-IV

Subarachnoid Haemorrhage

• Often self-limiting, good prognosis
• Diagnosis: CT or lumbar puncture (xanthochromia, red cells in CSF)

Neonatal Infections

Bacterial Sepsis/Meningitis

• Group B Streptococcus, E. coli, Listeria
• Maternal fever, prolonged rupture of membranes
• Blood/CSF cultures, elevated CRP, neutropenia
• Empirical antibiotics (ampicillin + gentamicin or cefotaxime)

Viral Encephalitis

• Herpes simplex virus (HSV): vesicular rash, seizures, focal temporal lobe lesions on MRI
• Enterovirus: seasonal, CSF pleocytosis
• PCR of CSF for diagnosis

Inborn Errors of Metabolism (IEM)

Urea Cycle Defects

• Hyperammonaemia (> 200 μmol/L), respiratory alkalosis
• Ornithine transcarbamylase (OTC) deficiency most common
• Plasma ammonia, urinary orotic acid, plasma amino acids

Organic Acidaemias

• Metabolic acidosis, hypoglycaemia, ketosis, hyperammonaemia
• Maple syrup urine disease (MSUD), propionic acidaemia, methylmalonic acidaemia
• Urine organic acids, plasma amino acids

Mitochondrial Disorders

• Leigh syndrome: basal ganglia lesions, elevated lactate
• Pyruvate dehydrogenase deficiency
• CSF/plasma lactate, MRS (lactate peak), genetic testing

Peroxisomal Disorders

• Zellweger syndrome: dysmorphism, hepatomegaly, seizures
• Very long chain fatty acids (VLCFA)

Neurological Disorders

Benign Familial Neonatal Epilepsy

• Seizures day 2-7, normal examination between seizures
• KCNQ2/KCNQ3 mutations
• Genetic testing

Early Infantile Epileptic Encephalopathy

• Severe early-onset epilepsy (Ohtahara syndrome, EIEE)
• Burst suppression on EEG
• Genetic panel (SCN2A, STXBP1, KCNQ2, ARX, etc.)

Neuromuscular Disorders

• Spinal muscular atrophy (SMA): Severe hypotonia, tongue fasciculations, normal cognition
• Congenital myopathies: Persistent hypotonia, often dysmorphic features
• Genetic testing, creatine kinase, electromyography

Endocrine/Metabolic

Hypoglycaemia

• Persistent hypoglycaemia can cause encephalopathy and seizures
• Check critical sample (insulin, cortisol, growth hormone, fatty acids, lactate)

Hypocalcaemia/Hypomagnesaemia

• Seizures, irritability
• Correct calcium/magnesium levels

Hyponatraemia

• Rare cause of seizures
• Usually iatrogenic (excessive free water)

Key Differentiating Features

---

7. Management

Overview: Neuroprotection and Supportive Care

Management of HIE centres on:

1. Therapeutic hypothermia: The only proven neuroprotective therapy
2. Seizure control: Minimize secondary injury from electrical seizures
3. Multiorgan supportive care: Maintain homeostasis during recovery
4. Avoidance of secondary injury: Hypoglycaemia, hypotension, hypo/hypercapnia, hyperthermia

Therapeutic Hypothermia

Eligibility Criteria

Cooling should be offered to infants meeting ALL of the following criteria: [9,10,39]

Inclusion Criteria

1. Gestation ≥ 36 weeks (or ≥ 35 weeks in some centres, off-label)
2. Postnatal age less than 6 hours at time of initiating cooling
3. Evidence of perinatal compromise (at least ONE of):
   • Apgar ≤ 5 at 10 minutes
   • Continued need for resuscitation at 10 minutes
   • Cord pH less than 7.0 or base deficit ≥ 16 mmol/L
   • Postnatal pH less than 7.0 or base deficit ≥ 16 mmol/L within 60 minutes of birth
4. Evidence of moderate or severe encephalopathy (Sarnat stage 2 or 3)
5. Abnormal aEEG (if available): Moderately or severely abnormal background

Exclusion Criteria

• Major congenital abnormality or life-limiting condition
• Severe growth restriction (less than 1800g in term infant suggests chronic pathology)
• Significant intracranial haemorrhage on initial imaging
• Moribund, death considered imminent

Passive Cooling (Pre-Transport)

Cooling should begin as soon as eligibility determined, even before transport to cooling centre:

1. Turn off radiant warmer on resuscitaire
2. Remove hat and clothing (leave nappy only)
3. Monitor rectal or oesophageal temperature continuously (target 33-34°C)
4. Avoid active cooling methods (ice packs, cold gel packs) - risk of overcooling
5. If temperature falls less than 33°C, cover infant partially to slow cooling
6. Document temperature every 15 minutes [40]

Active Cooling Protocol

Method: Whole-body cooling using servo-controlled cooling blanket/mattress (e.g., Tecotherm, Criticool, Arctic Sun)

Target Temperature: 33.5°C ± 0.5°C (rectal or oesophageal core temperature)

Duration: 72 hours from initiation

Monitoring During Cooling

• Continuous rectal/oesophageal temperature monitoring (servo-controlled)
• Skin temperature probes (monitor gradient, avoid skin injury)
• Continuous aEEG/EEG monitoring
• Continuous cardiac monitoring, blood pressure (arterial line preferred)
• Hourly documentation of vital signs, temperature, aEEG background
• Blood gases every 4-6 hours (maintain pH 7.35-7.45, PaCO₂ 5-6 kPa, lactate less than 2 mmol/L)
• Blood glucose 4-hourly
• Daily electrolytes, renal function, liver function, coagulation

Complications of Cooling

• Sinus bradycardia: Expected (heart rate 80-100 bpm acceptable), usually benign
• Coagulopathy: Hypothermia impairs clotting cascade; correct with FFP, cryoprecipitate if bleeding
• Thrombocytopenia: Transfuse platelets if less than 50 × 10⁹/L and bleeding
• Hypotension: Maintain mean BP > gestational age; inotropes if required
• Subcutaneous fat necrosis: Rare, presents weeks later as firm nodules (resolves spontaneously)
• Infection risk: No increased sepsis rate in RCTs, but maintain sterile techniques [41]

Rewarming

After 72 hours of cooling, gradual rewarming is essential to avoid complications:

• Rate: 0.5°C per hour
• Duration: 6-8 hours to reach normothermia (36.5-37°C)
• Monitoring: Increased seizures, hypotension, hyperkalaemia may occur during rewarming
• Once normothermic, maintain normothermia (avoid hyperthermia - associated with worse outcomes)

Post-Rewarming Care

• Continue supportive care until neurological recovery
• Wean ventilation, sedation, inotropes as tolerated
• Establish full enteral feeding (may take 7-14 days)
• MRI at day 5-10
• Neurodevelopmental follow-up arranged prior to discharge

Seizure Management

Seizures are common in moderate-severe HIE (50-70%) and contribute to secondary brain injury. Aggressive seizure treatment is warranted. [42,43]

Anticonvulsant Protocol

First-Line: Phenobarbital

• Loading dose: 20 mg/kg IV over 20 minutes
• If seizures persist after 30 minutes: Further doses of 10 mg/kg (up to total 40 mg/kg)
• Maintenance: 5 mg/kg/day IV/PO divided BD, start 12 hours after last loading dose
• Therapeutic level: 20-40 mg/L
• Side effects: Respiratory depression, hypotension (slow administration), sedation

Second-Line: Phenytoin

• Loading dose: 20 mg/kg IV over 60 minutes (cardiac monitoring essential - arrhythmia risk)
• Maintenance: 5 mg/kg/day divided BD
• Therapeutic level: 10-20 mg/L
• Contraindication: Cardiac dysfunction (use alternative)

Third-Line: Levetiracetam

• Loading dose: 40-60 mg/kg IV over 10 minutes
• Maintenance: 30-60 mg/kg/day divided BD
• Increasingly used as second-line (fewer cardiac side effects than phenytoin)
• No established therapeutic level

Fourth-Line: Midazolam Infusion

• Loading dose: 0.15 mg/kg IV
• Infusion: 0.1-0.4 mg/kg/hour
• Titrate to seizure control on EEG
• Risk: Respiratory depression, hypotension

Fourth-Line: Lidocaine Infusion

• Loading dose: 2 mg/kg IV over 10 minutes
• Infusion: 6 mg/kg/hour for 6 hours, then 4 mg/kg/hour for 12 hours, then 2 mg/kg/hour
• Useful if cardiac contraindication to phenytoin
• Side effects: Cardiac arrhythmia, seizures (paradoxical if overdose)

Emerging Therapies

• Bumetanide: GABA modulation, under investigation in trials
• Topiramate: Case reports, limited data
• Ketogenic diet: Not used in acute neonatal seizures

EEG Monitoring During Treatment

• Electrical seizures often persist despite clinical seizure cessation
• Continuous or serial EEG monitoring guides therapy
• Goal: Seizure freedom (no electrical seizures on EEG)
• If seizures continue despite multiple agents, aim for seizure reduction rather than complete suppression (polypharmacy risks)

Anticonvulsant Withdrawal

• If MRI shows extensive injury and EEG shows persistent epileptiform activity: Continue anticonvulsants long-term (risk of epilepsy)
• If MRI normal and EEG normalizes: Gradual wean and discontinuation (phenobarbital taper over weeks as outpatient)

Supportive Care: Organ System Approach

Respiratory Support

Mechanical Ventilation

• 50-70% of cooled infants require ventilation
• Indications: Apnoea, hypoxia, hypercapnia, recurrent seizures, need for sedation during cooling
• PaCO₂ target: 5-6 kPa (avoid hypocapnia less than 4 kPa - cerebral vasoconstriction worsens ischaemia; avoid hypercapnia > 7 kPa - cerebral vasodilation, oedema)
• PaO₂ target: 8-12 kPa (avoid hyperoxia - oxidative stress)
• Saturations: 92-95%
• Mode: Conventional ventilation (pressure-limited or volume-targeted), usually gentle settings
• Wean as encephalopathy improves (typically day 3-7)

Persistent Pulmonary Hypertension (PPHN)

• Occurs in 20-30% of moderate-severe HIE
• Diagnosis: Labile hypoxia, differential saturations (pre/post-ductal), echocardiography (right-to-left shunt, elevated pulmonary pressures)
• Management:
  • Optimal oxygenation and ventilation (avoid acidosis, hypoxia)
  • Inhaled nitric oxide (iNO) 20 ppm
  • Inotropes (dobutamine, milrinone)
  • Sildenafil (pulmonary vasodilator)
  • ECMO (extracorporeal membrane oxygenation) rarely required

Cardiovascular Support

Blood Pressure Management

• Target mean arterial pressure ≥ gestational age (e.g., ≥ 40 mmHg in 40-week infant)
• Arterial line for continuous monitoring (radial or umbilical artery)
• Impaired autoregulation makes BP management critical [26]

Volume Resuscitation

• 10 mL/kg 0.9% saline boluses if hypovolaemic (ensure adequate preload before inotropes)
• Avoid excessive fluid (risk of cerebral oedema, pulmonary oedema)

Inotropic Support (if hypotensive despite adequate volume)

• Dopamine: 5-20 μg/kg/min (first-line, increases BP and cardiac output)
• Dobutamine: 5-20 μg/kg/min (if myocardial dysfunction on echo)
• Adrenaline: 0.05-0.5 μg/kg/min (if refractory hypotension)
• Milrinone: 0.5-1 μg/kg/min (if severe cardiac dysfunction, reduces afterload)
• Guided by echocardiography, lactate, urine output

Fluid Management

• Restriction to 40-60 mL/kg/day in first 24-48 hours (risk of SIADH, cerebral oedema)
• Monitor urine output (target > 1 mL/kg/hour)
• Daily weights, strict fluid balance
• Adjust based on electrolytes (risk of hyponatraemia from SIADH)

Metabolic Management

Glucose Control

• Target: 2.6-10 mmol/L
• Hypoglycaemia less than 2.6 mmol/L: Increase dextrose concentration (10% dextrose), give bolus if less than 2.0 mmol/L
• Persistent hypoglycaemia despite high glucose infusion rates (> 8 mg/kg/min): Poor prognostic sign
• Hyperglycaemia > 10 mmol/L: Reduce dextrose concentration or consider insulin infusion (rare)

Electrolytes

• Sodium: 135-145 mmol/L; hyponatraemia common (SIADH), manage with fluid restriction
• Potassium: 3.5-5.5 mmol/L; hyperkalaemia common in AKI, manage with calcium resonium, dialysis if severe
• Calcium: Maintain ionized calcium 1.1-1.3 mmol/L (hypocalcaemia common, give IV calcium gluconate)
• Magnesium: Maintain > 0.7 mmol/L (required for calcium homeostasis)

Acid-Base

• Correct metabolic acidosis (pH less than 7.2) if persistent (sodium bicarbonate if base deficit > 10 despite adequate ventilation and perfusion)
• Usually improves with supportive care

Renal Support

Acute Kidney Injury (AKI) occurs in 40-50% of HIE [16]

• Monitor urine output hourly (insert urinary catheter)
• Daily creatinine (rising trend indicates AKI)
• Fluid restriction if oliguric (less than 1 mL/kg/hour)
• Avoid nephrotoxic drugs (gentamicin, NSAIDs)
• Peritoneal dialysis or haemofiltration if severe (anuria, hyperkalaemia > 7 mmol/L, severe acidosis, fluid overload)

Haematological Management

Coagulopathy/DIC

• Daily coagulation screen (PT, APTT, fibrinogen, platelets)
• Transfuse fresh frozen plasma (FFP) 10-20 mL/kg if PT/APTT prolonged AND bleeding
• Transfuse cryoprecipitate if fibrinogen less than 1.0 g/L
• Transfuse platelets if less than 50 × 10⁹/L AND bleeding, or less than 30 × 10⁹/L

Anaemia

• Transfuse packed red cells if Hb less than 120 g/L and ventilated, or less than 100 g/L and symptomatic

Nutritional Support

Enteral Feeding

• Delayed due to ileus, risk of NEC, need for ventilation
• Start minimal enteral feeds (trophic feeds 10-20 mL/kg/day) once cardiovascular stable and off inotropes (typically day 3-5)
• Advance slowly (20 mL/kg/day) if tolerated
• Maternal breastmilk preferred (donor milk or preterm formula if unavailable)
• Full feeds (150-180 mL/kg/day) often achieved by day 7-14

Parenteral Nutrition

• Start by day 2-3 if enteral feeds delayed
• Protein 2-3 g/kg/day, lipids 2-3 g/kg/day, dextrose to meet energy requirements
• Monitor electrolytes, triglycerides, liver function

Infection Prevention

Antibiotics

• Empirical antibiotics (ampicillin + gentamicin or cefotaxime) started if:
  • Sepsis risk factors present (maternal fever, prolonged rupture of membranes)
  • Cannot distinguish encephalopathy from sepsis
• Blood and CSF cultures before antibiotics (lumbar puncture if stable)
• Discontinue at 48 hours if cultures negative and clinical picture consistent with HIE
• Continue if sepsis confirmed or strongly suspected

Line Care

• Aseptic technique for central lines, arterial lines
• Daily review of line necessity, remove as soon as possible

Emerging Neuroprotective Therapies

While therapeutic hypothermia is the only established neuroprotective treatment, several adjunctive therapies are under investigation:

Erythropoietin (EPO)

• Neuroprotective mechanisms: Anti-apoptotic, anti-inflammatory, promotes neurogenesis
• Dosing regimens: Variable in trials (500-2500 U/kg, multiple doses)
• Evidence: Meta-analysis shows trend toward improved outcomes when combined with cooling, ongoing trials (e.g., HEAL trial) [44]
• Not yet standard of care

Melatonin

• Antioxidant, anti-inflammatory, mitochondrial protective
• Dose: 10 mg/kg/dose over 6 hours, repeated (in trials)
• Small pilot studies suggest safety and potential benefit
• Larger trials needed [45]

Xenon

• Inhaled noble gas with NMDA antagonist properties
• Combined with hypothermia in trials
• Technical challenges, expensive, limited availability
• Conflicting trial results (TOBY-Xe neutral) [46]

Allopurinol

• Xanthine oxidase inhibitor, reduces free radical production
• Maternal administration during labour (if fetal compromise detected)
• ALLO trial: No benefit in postnatal administration
• Antenatal trials ongoing

Stem Cell Therapy

• Autologous cord blood, mesenchymal stem cells
• Mechanisms: Paracrine effects, modulation of inflammation, promote repair
• Early-phase trials ongoing
• Significant logistical and regulatory challenges

---

8. Prognosis and Outcomes

Short-Term Outcomes

Mortality

• Overall mortality (moderate-severe HIE): 10-30% in cooling era
• Moderate HIE (Sarnat 2): 5-10% mortality
• Severe HIE (Sarnat 3): 50-60% mortality despite cooling
• Withdrawal of life-sustaining treatment: Difficult decision, requires multidisciplinary input, neuroprognostication tools [47]

Long-Term Neurodevelopmental Outcomes

Cerebral Palsy (CP)

• Most common motor outcome
• Incidence in cooled HIE survivors: 15-25% (compared to 30-40% without cooling)
• Types:
  • "Dyskinetic CP: Basal ganglia-thalamus injury, involuntary movements, dystonia, athetosis"
  • "Spastic quadriplegia: Watershed injury, increased tone, limited mobility"
  • "Hemiplegia: Focal stroke co-existing with HIE"
• GMFCS (Gross Motor Function Classification System): Grades severity I-V
• Associated impairments: Feeding difficulties, speech problems, contractures

Cognitive Impairment

• Intellectual disability: 10-20% of cooled survivors
• Learning difficulties, executive dysfunction even in children without CP
• Subtle deficits may not be apparent until school age

Epilepsy

• 10-30% of survivors develop epilepsy
• Higher risk if extensive cortical injury on MRI
• May be focal or generalized

Visual Impairment

• Cortical visual impairment (CVI): Most common form
• Optic nerve atrophy, retinopathy less common
• Ophthalmology follow-up essential

Hearing Impairment

• Sensorineural hearing loss: 2-5% of survivors
• Auditory neuropathy spectrum disorder
• Newborn hearing screening, audiology follow-up

Behavioural and Psychiatric Outcomes

• ADHD, autism spectrum disorder increased incidence
• Anxiety, mood disorders in adolescence

Prognostic Factors

Clinical Factors

• Sarnat stage: Severe encephalopathy (stage 3) much worse prognosis than moderate (stage 2)
• Severity of acidosis: pH less than 6.8, base deficit > 20 associated with poor outcome
• Multiorgan failure: Extent of extracerebral organ involvement correlates with brain injury severity [16]
• Time to first gasp/breath: Prolonged apnoea (> 20 minutes) poor prognostic sign

Electrophysiological Factors

• aEEG background:
  • "Normal voltage by 24 hours: 90% normal outcome"
  • "Persistent burst suppression or worse at 48-72 hours: 80% death/severe disability [14]"
• EEG background and seizures: Severe background abnormality, status epilepticus predict poor outcome

Imaging Factors

• MRI patterns [15,37]:
  • "Normal MRI: > 95% normal outcome"
  • "Mild watershed injury: 70-80% normal outcome"
  • "Severe BGT injury (Barkovich score 3-4): 5-10% normal outcome"
  • "Combined BGT + watershed injury: Worst prognosis"
• MRS lactate/NAA: Elevated lactate, reduced NAA predict adverse outcome [36]

Biomarkers

• Elevated NSE, S100B, GFAP associated with worse outcomes, but insufficient sensitivity/specificity for individual prognostication [33]

Neuroprognostication

Accurate outcome prediction is essential for counselling families and planning interventions. No single test is perfectly predictive; multimodal assessment recommended. [48]

Optimal Timing: After 72 hours (end of cooling), ideally after rewarming

Multimodal Approach:

1. Clinical examination: Persistent severe encephalopathy at 72-96 hours
2. aEEG/EEG: Background pattern at 48-72 hours
3. MRI: Day 5-10, anatomical scoring
4. MRS: Lactate/NAA ratios
5. Clinical evolution: Improvement vs deterioration over first week

Favourable Outcome Predictors (Normal development likely):

• Normal or mildly abnormal aEEG by 24 hours
• Normal MRI at day 7-10
• Clinical improvement, normal examination by 1 week

Unfavourable Outcome Predictors (Death or severe disability likely):

• Flat trace or continuous low voltage aEEG at 48 hours
• Severe BGT injury on MRI (Barkovich 3-4)
• Persistent severe encephalopathy at 1 week
• Absent Moro reflex at 72 hours [47]

Neurodevelopmental Follow-Up

All infants with HIE require structured long-term follow-up:

Schedule:

• 3 months: Clinical assessment, feeding evaluation
• 6 months: Developmental assessment, hearing/vision screening
• 12 months: Formal developmental testing (Bayley Scales), CP surveillance
• 18-24 months: CP diagnosis, early intervention planning
• School age: Cognitive assessment, educational support needs

Multidisciplinary Team:

• Paediatrician/neonatologist
• Physiotherapist (motor development, CP management)
• Occupational therapist (fine motor, activities of daily living)
• Speech and language therapist (feeding, communication)
• Psychologist (cognitive assessment, behavioural support)
• Ophthalmology, audiology
• Social worker, family support

Early Intervention:

• Physiotherapy for motor delays, prevention of contractures
• Feeding support (may require gastrostomy if unsafe swallow)
• Antiepileptic medication if seizures develop
• Consideration of Botulinum toxin, baclofen, or orthopaedic surgery for spasticity management in CP

---

9. Evidence and Guidelines

Key Clinical Guidelines

Landmark Trials: Therapeutic Hypothermia

1. TOBY Trial (Whole-Body Hypothermia for Neonates with HIE) - 2009 [9]

• Design: RCT, 325 infants, whole-body cooling 33-34°C for 72 hours vs standard care
• Primary outcome: Death or severe disability at 18 months
• Results:
  • "Cooling group: 45% death/disability"
  • "Control group: 53% death/disability"
  • RR 0.86 (95% CI 0.68-1.07), p=0.17 (trend favouring cooling)
  • "Secondary analysis: Reduced combined outcome of death or CP (p=0.04)"
• Impact: Established whole-body cooling as viable neuroprotective strategy

2. NICHD Trial (Whole-Body Hypothermia) - 2005 [51]

• Design: RCT, 208 infants, cooling to 33.5°C for 72 hours
• Primary outcome: Death or moderate-severe disability at 18-22 months
• Results:
  • "Cooling: 44% death/disability"
  • "Control: 62% death/disability"
  • RR 0.72 (95% CI 0.54-0.95), p=0.01
• Impact: First major trial demonstrating efficacy of cooling, changed practice

3. CoolCap Trial (Selective Head Cooling) - 2005 [52]

• Design: RCT, 234 infants, selective head cooling with mild systemic hypothermia vs standard care
• Results: Primary outcome not significantly different, but trend favouring cooling in subgroup with less severe aEEG changes
• Impact: Selective head cooling less widely adopted than whole-body cooling

4. ICE Trial (Infant Cooling Evaluation) - 2008 [53]

• Design: RCT, 221 infants, whole-body cooling 33-34°C
• Results: Reduced mortality (OR 0.57), no significant effect on disability in survivors
• Impact: Further supported cooling efficacy

5. Meta-Analysis (Cochrane Review) - 2013 [10]

• Design: Systematic review of 11 RCTs, 1505 infants
• Results:
  • "Cooling reduces death or major disability: RR 0.75 (95% CI 0.68-0.83), NNT = 7"
  • "Reduced mortality: RR 0.75 (95% CI 0.64-0.88)"
  • "Reduced CP in survivors: RR 0.67 (95% CI 0.54-0.84)"
• Impact: Definitive evidence establishing therapeutic hypothermia as standard of care

Subsequent Trials and Ongoing Research

TOBY-Xe Trial (Xenon + Hypothermia) - 2016 [46]

• Adding xenon to cooling did not improve outcomes (neutral result)

HEAL Trial (Erythropoietin + Hypothermia) - Ongoing

• Investigating high-dose EPO as adjunct to cooling [44]

HELIX Trial (Hypothermia for HIE in Low-Income Countries) - 2021 [54]

• Cooling in low-resource settings: Increased mortality (trial stopped early)
• Highlights importance of intensive care infrastructure for safe cooling implementation

Optimising Cooling Trials

• Longer cooling duration (96-120 hours): No additional benefit
• Deeper cooling (32°C): Increased adverse events without improved outcomes
• Late cooling (6-24 hours): Reduced efficacy

---

10. Prevention

Intrapartum Monitoring and Intervention

Continuous Fetal Monitoring

• Cardiotocography (CTG) in labour for high-risk pregnancies
• Early detection of fetal compromise (bradycardia, late decelerations)
• Fetal scalp blood sampling (FBS) if abnormal CTG (pH less than 7.2 indicates acidosis, expedite delivery)

Timely Intervention

• Emergency caesarean section if fetal compromise detected (decision-to-delivery interval less than 30 minutes)
• Instrumental delivery (forceps, ventouse) for prolonged second stage with fetal compromise
• Management of sentinel events (abruption, cord prolapse) with immediate delivery

Obstetric Risk Factor Management

• Pre-eclampsia monitoring and treatment (prevent placental abruption)
• Diabetes control (reduce macrosomia and shoulder dystocia risk)
• Appropriate timing of delivery in high-risk pregnancies (IUGR, placental insufficiency)

Neonatal Resuscitation

Skilled Resuscitation Team

• Neonatal team present at all high-risk deliveries
• Adherence to Neonatal Resuscitation Programme (NRP) guidelines
• Effective ventilation within first minute of life critical
• Avoid prolonged futile resuscitation (if no heart rate by 20 minutes, poor prognosis) [19]

Delayed Cord Clamping

• Placental transfusion may improve outcomes (> 60 seconds)
• Balance with need for immediate resuscitation

---

11. Special Considerations

Late Preterm Infants (35-36 Weeks)

• Cooling trials included infants ≥ 36 weeks
• Off-label cooling at 35-36 weeks increasingly practiced (some centres offer cooling at ≥ 35 weeks)
• Higher risk of complications (hypoglycaemia, respiratory distress)
• Individual case-by-case decision [39]

Low-Resource Settings

• HELIX trial showed increased mortality with cooling in low-resource settings (inadequate intensive care support) [54]
• Passive cooling (low-cost) being investigated
• Infrastructure (mechanical ventilation, inotropes, monitoring) essential for safe cooling

Medicolegal Considerations

• HIE cases frequently subject to litigation
• Meticulous documentation essential:
  • Detailed intrapartum events, timing of sentinel event
  • CTG traces, fetal blood sampling results
  • Cord gases (umbilical artery and vein)
  • Resuscitation details (Apgar scores, interventions, timings)
  • Neurological examination findings (Sarnat stage)
  • Decision-making process for cooling
• Honest communication with families
• Root cause analysis and learning from cases to prevent future events

---

12. Patient and Family Communication

Explaining HIE to Parents

What Happened? "During labour/delivery, your baby experienced a period when they did not receive enough oxygen. This lack of oxygen affected the brain and other organs. We call this hypoxic ischaemic encephalopathy, or HIE. It can happen due to complications during birth, such as problems with the placenta or umbilical cord."

Why Cooling Treatment? "Research has shown that gently cooling babies who have HIE can protect the brain and improve outcomes. We lower your baby's body temperature to 33.5 degrees for 3 days. This slows down the brain's activity and reduces further damage. It's like putting the brain into 'hibernation' to give it time to heal."

What to Expect "Your baby will be in the neonatal intensive care unit, connected to monitors and possibly a breathing machine. They may look unwell and need medications to control seizures or support blood pressure. The cooling treatment lasts 72 hours, then we gradually warm them back to normal temperature. During this time, we're providing all the support their body needs while the brain recovers."

Will My Baby Be Okay? "It's difficult to predict the future in the early days. Some babies recover completely with no long-term problems. Others may have ongoing difficulties with movement, learning, vision, or hearing. After the cooling treatment, we'll do an MRI scan of the brain, which gives us the best information about how much injury occurred. We'll follow your baby closely as they grow and provide support for any developmental needs."

Supporting Families

• Emotional support: Social work, chaplaincy, parent support groups
• Involvement in care: Encourage skin-to-skin contact once stable, provide breastmilk, parental presence
• Honest communication: Regular updates, realistic expectations, acknowledge uncertainty
• Long-term planning: Early discussion of follow-up, therapies, support services
• Sibling support: Consider needs of siblings, family-centred care

---

13. Examination Focus

Common Exam Scenarios

OSCE/Clinical Examination Station

• "Examine this 3-day-old infant who required resuscitation at birth and is receiving therapeutic hypothermia"
• Demonstrate systematic neurological examination: Tone, primitive reflexes, level of consciousness
• Identify signs of encephalopathy (hypotonia, absent Moro reflex)
• Recognize cooling equipment, temperature monitoring

MCQ/SBA High-Yield Topics

1. Criteria for therapeutic hypothermia: Gestation ≥ 36 weeks, age less than 6 hours, evidence of asphyxia (pH less than 7.0 or Apgar ≤ 5 at 10 min), moderate-severe encephalopathy
2. Best prognostic investigation: MRI brain at day 5-10
3. Regions of brain injury: Basal ganglia-thalamus (acute profound hypoxia-ischaemia), watershed (partial prolonged)
4. First-line anticonvulsant: Phenobarbital 20 mg/kg IV
5. Cooling target and duration: 33.5°C for 72 hours
6. Rewarming rate: 0.5°C per hour
7. Outcome predictors: aEEG background at 48 hours, MRI injury pattern
8. Associated complications: Multi-organ dysfunction (renal failure, hepatic injury, cardiac dysfunction, DIC)

Viva Voce Topics

Pathophysiology

• Explain the biphasic injury pattern in HIE
• "Describe the mechanism of secondary energy failure"
• "What is excitotoxicity and why is the neonatal brain particularly vulnerable?"

Therapeutic Hypothermia

• "Why is there a 6-hour therapeutic window?"
  • "Answer: Based on animal models demonstrating that secondary energy failure begins 6 hours after the insult. Cooling interrupts cascade of excitotoxicity, oxidative stress, inflammation, and apoptosis."
• "What are the potential complications of cooling?"
  • "Answer: Sinus bradycardia (expected, usually benign), coagulopathy (hypothermia impairs clotting), thrombocytopenia, hypotension, subcutaneous fat necrosis (rare), potential increased infection risk (not confirmed in trials)."

Prognostication

• "How do you counsel parents about long-term outcomes in the first week of life?"
  • "Answer: Emphasize uncertainty in early days, explain multimodal assessment (clinical exam, aEEG, MRI), provide realistic range of outcomes (normal to severe disability), explain follow-up plan."
• "What imaging findings predict poor outcome?"
  • "Answer: Severe basal ganglia-thalamus injury (Barkovich score 3-4), extensive watershed injury, combined patterns, absent signal on DWI indicating extensive infarction."

Ethical Considerations

• "When might you consider withdrawal of life-sustaining treatment?"
  • "Answer: Severe HIE with devastating MRI findings (extensive bilateral injury), persistent severe encephalopathy beyond 1-2 weeks, multi-organ failure, family wishes after full counselling. Requires multidisciplinary discussion, senior input, consideration of multimodal prognostic factors. Acknowledge difficulty and uncertainty."

Clinical Pearls for Exams

The 6-Hour Rule "Therapeutic hypothermia is only effective if started within 6 hours of birth, based on animal studies showing that secondary energy failure mechanisms become irreversible after this time window."

MRI Day 5-10 is Gold Standard "Early MRI (less than 4 days) may underestimate injury. Optimal timing is day 5-10 when patterns of injury are fully established and correlate best with neurodevelopmental outcomes."

aEEG at 48 Hours Predicts Outcome "An aEEG showing burst suppression or worse at 48 hours has 80% positive predictive value for death or severe disability, whereas normal voltage trace predicts normal outcome in > 90%."

Phenobarbital 20 mg/kg is First-Line "Phenobarbital loading dose 20 mg/kg IV is first-line treatment for neonatal seizures in HIE. Further doses of 10 mg/kg up to total 40 mg/kg can be given if seizures persist."

Multi-Organ is the Rule, Not the Exception "HIE is a systemic condition: 50% have acute kidney injury, 40% hepatic dysfunction, 30% cardiac dysfunction, 20% DIC. Always monitor renal function, liver enzymes, coagulation, and cardiac function."

---

14. Key Take-Home Messages

1. HIE is a time-critical neurological emergency: Therapeutic hypothermia must be initiated within 6 hours of birth to modify outcome.

2. Biphasic injury: Primary energy failure during hypoxia-ischaemia, followed by delayed secondary energy failure (6-48 hours) mediated by excitotoxicity, oxidative stress, inflammation, and apoptosis.

3. Therapeutic hypothermia is the only proven neuroprotective treatment: Cooling to 33.5°C for 72 hours reduces death or disability by 25% (NNT = 7).

4. Sarnat staging guides treatment: Moderate (stage 2) or severe (stage 3) encephalopathy qualifies for cooling; mild (stage 1) does not.

5. Passive cooling during transfer: Turn off radiant warmer, remove clothing, monitor rectal temperature (target 33-34°C) while arranging transport to cooling centre.

6. Multi-organ involvement is universal: Monitor and support renal, hepatic, cardiac, haematological, and respiratory function.

7. Seizure control is critical: Phenobarbital 20 mg/kg IV first-line; treat electrical seizures detected on aEEG/EEG even if no clinical manifestations.

8. MRI at day 5-10 is the best prognostic tool: Basal ganglia-thalamus injury indicates poor prognosis (dyskinetic CP); normal MRI predicts normal outcome in > 95%.

9. Neuroprognostication requires multimodal assessment: Combine clinical examination, aEEG background (48-72 hours), MRI patterns, MRS, and clinical evolution.

10. Long-term neurodevelopmental follow-up is essential: All infants with HIE require structured surveillance for cerebral palsy, epilepsy, cognitive impairment, and sensory deficits.

---

15. References

Primary Sources

1. Volpe JJ. Neonatal encephalopathy: an inadequate term for hypoxic-ischemic encephalopathy. Ann Neurol. 2012;72(2):156-166. doi:10.1002/ana.23647

2. Douglas-Escobar M, Weiss MD. Hypoxic-ischemic encephalopathy: a review for the clinician. JAMA Pediatr. 2015;169(4):397-403. doi:10.1001/jamapediatrics.2014.3269

3. Lawn JE, Cousens S, Zupan J; Lancet Neonatal Survival Steering Team. 4 million neonatal deaths: when? Where? Why? Lancet. 2005;365(9462):891-900. doi:10.1016/S0140-6736(05)71048-5

4. Kurinczuk JJ, White-Koning M, Badawi N. Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy. Early Hum Dev. 2010;86(6):329-338. doi:10.1016/j.earlhumdev.2010.05.010

5. Lee AC, Kozuki N, Blencowe H, et al. Intrapartum-related neonatal encephalopathy incidence and impairment at regional and global levels for 2010 with trends from 1990. Pediatr Res. 2013;74 Suppl 1:50-72. doi:10.1038/pr.2013.206

6. Pierrat V, Haouari N, Liska A, Thomas D, Subtil D, Truffert P; Groupe d'Etudes en Epidemiologie Perinatale. Prevalence, causes, and outcome at 2 years of age of newborn encephalopathy: population based study. Arch Dis Child Fetal Neonatal Ed. 2005;90(3):F257-F261. doi:10.1136/adc.2003.047985

7. Lorek A, Takei Y, Cady EB, et al. Delayed ("secondary") cerebral energy failure after acute hypoxia-ischemia in the newborn piglet: continuous 48-hour studies by phosphorus magnetic resonance spectroscopy. Pediatr Res. 1994;36(6):699-706. doi:10.1203/00006450-199412000-00003

8. Gunn AJ, Wyatt JS, Whitelaw A, et al. Therapeutic hypothermia changes the prognostic value of fetal acidosis and delayed onset of cerebral energy failure in newborns with hypoxic-ischemic encephalopathy. Pediatrics. 2008;121(5):1025-1031. doi:10.1542/peds.2007-2888

9. Azzopardi DV, Strohm B, Edwards AD, et al; TOBY Study Group. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med. 2009;361(14):1349-1358. doi:10.1056/NEJMoa0900854

10. Jacobs SE, Berg M, Hunt R, Tarnow-Mordi WO, Inder TE, Davis PG. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst Rev. 2013;2013(1):CD003311. doi:10.1002/14651858.CD003311.pub3

11. Perlman JM, Wyllie J, Kattwinkel J, et al; Neonatal Resuscitation Chapter Collaborators. Part 7: Neonatal Resuscitation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2015;132(16 Suppl 1):S204-S241. doi:10.1161/CIR.0000000000000276

12. Sarnat HB, Sarnat MS. Neonatal encephalopathy following fetal distress. A clinical and electroencephalographic study. Arch Neurol. 1976;33(10):696-705. doi:10.1001/archneur.1976.00500100030012

13. Gunn AJ, Bennet L. Timing of injury in the fetus and neonate. Curr Opin Obstet Gynecol. 2008;20(2):175-181. doi:10.1097/GCO.0b013e3282f6016f

14. Hellström-Westas L, Rosén I, de Vries LS, Greisen G. Amplitude-integrated EEG classification and interpretation in preterm and term infants. NeoReviews. 2006;7(2):e76-e87. doi:10.1542/neo.7-2-e76

15. Barkovich AJ, Hajnal BL, Vigneron D, et al. Prediction of neuromotor outcome in perinatal asphyxia: evaluation of MR scoring systems. AJNR Am J Neuroradiol. 1998;19(1):143-149.

16. Karlsson M, Wiberg-Itzel E, Chakkarapani E, Blennow M, Winbladh B, Thoresen M. Lactate dehydrogenase predicts hypoxic ischaemic encephalopathy in newborn infants: a preliminary study. Acta Paediatr. 2010;99(8):1139-1144. doi:10.1111/j.1651-2227.2010.01802.x

17. Lawn J, Shibuya K, Stein C. No cry at birth: global estimates of intrapartum stillbirths and intrapartum-related neonatal deaths. Bull World Health Organ. 2005;83(6):409-417.

18. Badawi N, Kurinczuk JJ, Keogh JM, et al. Antepartum risk factors for newborn encephalopathy: the Western Australian case-control study. BMJ. 1998;317(7172):1549-1553. doi:10.1136/bmj.317.7172.1549

19. Wyckoff MH, Aziz K, Escobedo MB, et al. Part 13: Neonatal Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015;132(18 Suppl 2):S543-S560. doi:10.1161/CIR.0000000000000267

20. Vannucci RC. Hypoxic-ischemic encephalopathy. Am J Perinatol. 2000;17(3):113-120. doi:10.1055/s-2000-9293

21. Johnston MV, Trescher WH, Ishida A, Nakajima W. Neurobiology of hypoxic-ischemic injury in the developing brain. Pediatr Res. 2001;49(6):735-741. doi:10.1203/00006450-200106000-00003

22. Hope PL, Costello AM, Cady EB, et al. Cerebral energy metabolism studied with phosphorus NMR spectroscopy in normal and birth-asphyxiated infants. Lancet. 1984;2(8399):366-370. doi:10.1016/s0140-6736(84)90539-7

23. Shalak L, Perlman JM. Hypoxic-ischemic brain injury in the term infant-current concepts. Early Hum Dev. 2004;80(2):125-141. doi:10.1016/j.earlhumdev.2004.06.003

24. Hagberg H, Mallard C, Ferriero DM, et al. The role of inflammation in perinatal brain injury. Nat Rev Neurol. 2015;11(4):192-208. doi:10.1038/nrneurol.2015.13

25. Northington FJ, Ferriero DM, Graham EM, Traystman RJ, Martin LJ. Early neurodegeneration after hypoxia-ischemia in neonatal rat is necrosis while delayed neuronal death is apoptosis. Neurobiol Dis. 2001;8(2):207-219. doi:10.1006/nbdi.2000.0371

26. Pryds O, Greisen G, Lou H, Frils-Hansen B. Heterogeneity of cerebral vasoreactivity in preterm infants supported by mechanical ventilation. J Pediatr. 1989;115(4):638-645. doi:10.1016/s0022-3476(89)80301-4

27. Sie LT, van der Knaap MS, Oosting J, de Vries LS, Lafeber HN, Valk J. MR patterns of hypoxic-ischemic brain damage after prenatal, perinatal or postnatal asphyxia. Neuropediatrics. 2000;31(3):128-136. doi:10.1055/s-2000-7496

28. Thoresen M, Tooley J, Liu X, et al. Time is brain: starting therapeutic hypothermia within three hours after birth improves motor outcome in asphyxiated newborns. Neonatology. 2013;104(3):228-233. doi:10.1159/000353948

29. Ehrenstein V, Pedersen L, Grijota M, Nielsen GL, Rothman KJ, Sørensen HT. Association of Apgar score at five minutes with long-term neurologic disability and cognitive function in a prevalence study of Danish conscripts. BMC Pregnancy Childbirth. 2009;9:14. doi:10.1186/1471-2393-9-14

30. Volpe JJ. Neurology of the Newborn. 5th ed. Saunders Elsevier; 2008.

31. Toet MC, Hellström-Westas L, Groenendaal F, Eken P, de Vries LS. Amplitude integrated EEG 3 and 6 hours after birth in full term neonates with hypoxic-ischaemic encephalopathy. Arch Dis Child Fetal Neonatal Ed. 1999;81(1):F19-F23. doi:10.1136/fn.81.1.f19

32. Murray DM, Boylan GB, Ryan CA, Connolly S. Early EEG findings in hypoxic-ischemic encephalopathy predict outcomes at 2 years. Pediatrics. 2009;124(3):e459-e467. doi:10.1542/peds.2008-2190

33. Chalak LF, Sánchez PJ, Adams-Huet B, Laptook AR, Heyne RJ, Rosenfeld CR. Biomarkers for severity of neonatal hypoxic-ischemic encephalopathy and outcomes in newborns receiving hypothermia therapy. J Pediatr. 2014;164(3):468-474.e1. doi:10.1016/j.jpeds.2013.10.067

34. Epelman M, Daneman A, Kellenberger CJ, et al. Neonatal encephalopathy: a prospective comparison of head US and MRI. Pediatr Radiol. 2010;40(10):1640-1650. doi:10.1007/s00247-010-1634-6

35. Rutherford M, Ramenghi LA, Edwards AD, et al. Assessment of brain tissue injury after moderate hypothermia in neonates with hypoxic-ischaemic encephalopathy: a nested substudy of a randomised controlled trial. Lancet Neurol. 2010;9(1):39-45. doi:10.1016/S1474-4422(09)70295-9

36. Thayyil S, Chandrasekaran M, Taylor A, et al. Cerebral magnetic resonance biomarkers in neonatal encephalopathy: a meta-analysis. Pediatrics. 2010;125(2):e382-e395. doi:10.1542/peds.2009-1046

37. Shankaran S, Barnes PD, Hintz SR, et al; Eunice Kennedy Shriver NICHD Neonatal Research Network. Brain injury following trial of hypothermia for neonatal hypoxic-ischaemic encephalopathy. Arch Dis Child Fetal Neonatal Ed. 2012;97(6):F398-F404. doi:10.1136/archdischild-2011-301524

38. Finder M, Boylan GB, Twomey D, Ahearne C, Murray DM, Hallberg B. Two-year neurodevelopmental outcomes after mild hypoxic ischemic encephalopathy in the era of therapeutic hypothermia. JAMA Pediatr. 2020;174(1):48-55. doi:10.1001/jamapediatrics.2019.4011

39. British Association of Perinatal Medicine. Therapeutic Hypothermia for Neonatal Encephalopathy. BAPM Framework for Practice. 2022. Accessed January 6, 2026.

40. Kendall GS, Kapetanakis A, Ratnavel N, Azzopardi D, Robertson NJ; Cooling on Retrieval Study Group. Passive cooling for initiation of therapeutic hypothermia in neonatal encephalopathy. Arch Dis Child Fetal Neonatal Ed. 2010;95(6):F408-F412. doi:10.1136/adc.2010.187211

41. Azzopardi D, Strohm B, Linsell L, et al; TOBY Study Group. Implementation and conduct of therapeutic hypothermia for perinatal asphyxial encephalopathy in the UK--analysis of national data. PLoS One. 2012;7(6):e38504. doi:10.1371/journal.pone.0038504

42. Glass HC, Glidden D, Jeremy RJ, Barkovich AJ, Ferriero DM, Miller SP. Clinical Neonatal Seizures are Independently Associated with Outcome in Infants at Risk for Hypoxic-Ischemic Brain Injury. J Pediatr. 2009;155(3):318-323. doi:10.1016/j.jpeds.2009.03.040

43. Vesoulis ZA, Mathur AM. Noninvasive EEG monitoring for seizure detection in neonatal intensive care unit. Pediatr Neurol. 2020;111:29-35. doi:10.1016/j.pediatrneurol.2020.06.011

44. Wu YW, Mathur AM, Chang T, et al; HEAL Consortium. High-Dose Erythropoietin and Hypothermia for Hypoxic-Ischemic Encephalopathy: A Phase II Trial. Pediatrics. 2016;137(6):e20160191. doi:10.1542/peds.2016-0191

45. Robertson NJ, Martinello K, Lingam I, et al. Melatonin as an adjunct to therapeutic hypothermia in a piglet model of neonatal encephalopathy: a translational study. Neurobiol Dis. 2019;121:240-251. doi:10.1016/j.nbd.2018.10.004

46. Azzopardi D, Robertson NJ, Bainbridge A, et al. Moderate hypothermia within 6 h of birth plus inhaled xenon versus moderate hypothermia alone after birth asphyxia (TOBY-Xe): a proof-of-concept, open-label, randomised controlled trial. Lancet Neurol. 2016;15(2):145-153. doi:10.1016/S1474-4422(15)00347-6

47. Lemmon ME, Wagner MW, Bosemani T, et al. Diffusion tensor imaging detects occult cerebellar injury in severe neonatal hypoxic-ischemic encephalopathy. Dev Neurosci. 2017;39(1-4):207-214. doi:10.1159/000454856

48. Committee on Fetus and Newborn, Papile LA, Baley JE, Benitz W, et al. Hypothermia and neonatal encephalopathy. Pediatrics. 2014;133(6):1146-1150. doi:10.1542/peds.2014-0899

49. National Institute for Health and Care Excellence. Therapeutic hypothermia with intracorporeal temperature monitoring for hypoxic perinatal brain injury. Interventional procedures guidance [IPG347]. 2010. Updated 2019.

50. World Health Organization. Guidelines on Neonatal Seizures. WHO; 2011.

51. Shankaran S, Laptook AR, Ehrenkranz RA, et al; National Institute of Child Health and Human Development Neonatal Research Network. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med. 2005;353(15):1574-1584. doi:10.1056/NEJMcps050929

52. Gluckman PD, Wyatt JS, Azzopardi D, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet. 2005;365(9460):663-670. doi:10.1016/S0140-6736(05)17946-X

53. Simbruner G, Mittal RA, Rohlmann F, Muche R; neo.nEURO.network Trial Participants. Systemic hypothermia after neonatal encephalopathy: outcomes of neo.nEURO.network RCT. Pediatrics. 2010;126(4):e771-e778. doi:10.1542/peds.2009-2441

54. Thayyil S, Pant S, Montaldo P, et al; HELIX consortium. Hypothermia for moderate or severe neonatal encephalopathy in low-income and middle-income countries (HELIX): a randomised controlled trial in India, Sri Lanka, and Bangladesh. Lancet Glob Health. 2021;9(9):e1273-e1285. doi:10.1016/S2214-109X(21)00264-3

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and follow local guidelines.